TY - JOUR
T1 - Management of hepatitis C virus genotype 4
T2 - Recommendations of An International Expert Panel
AU - Khattab, Mahmoud A.
AU - Ferenci, Peter
AU - Hadziyannis, Stephanos J.
AU - Colombo, Massimo
AU - Manns, Michael P.
AU - Almasio, Piero L.
AU - Esteban, Rafael
AU - Abdo, Ayman A.
AU - Harrison, Stephen A.
AU - Ibrahim, Nazir
AU - Cacoub, Patrice
AU - Eslam, Mohammed
AU - Lee, Samuel S.
PY - 2011/6
Y1 - 2011/6
N2 - HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in the world, it has not been the subject of widespread research. Therefore, this document, drafted by a panel of international experts, aimed to review current knowledge on the epidemiology, natural history, clinical, histological features, and treatment of HCV-4 infections.
AB - HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in the world, it has not been the subject of widespread research. Therefore, this document, drafted by a panel of international experts, aimed to review current knowledge on the epidemiology, natural history, clinical, histological features, and treatment of HCV-4 infections.
UR - http://www.scopus.com/inward/record.url?scp=79956074037&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79956074037&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2010.11.016
DO - 10.1016/j.jhep.2010.11.016
M3 - Article
C2 - 21316497
AN - SCOPUS:79956074037
VL - 54
SP - 1250
EP - 1262
JO - Journal of Hepatology
JF - Journal of Hepatology
SN - 0168-8278
IS - 6
ER -